Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Skyrizi Market from 2024 to 2025?
Over the recent years, the market size for Skyrizi has expanded at a rate of XX (HCAGR). It is projected to grow from $XX million in 2024 to $XX million in 2025, delivering a compound annual growth rate (CAGR) of XX%. The surge in growth during the historic period can be traced back to a heightened awareness of chronic inflammatory conditions, a surge in the development of biosimilars, improved access to global healthcare, broadening clinical indications, and an increase in long-term safety data.
What Is the Projected Market Size of the Skyrizi Market?
Expectations for the Skyrizi market’s expansion reveal XX (FCAGR) for the approaching years. By 2029, the projection sits at $XX million with a Compound Annual Growth Rate (CAGR) of XX%. Several factors contribute to this predicted growth during the forecast period including increased usage in psoriasis treatments, a rise in the number of affected patients, an ageing demographic, enhanced awareness alongside improved diagnostics, and an uptick in the consumption of processed foods. The forecast period may also observe significant trends such as biologic technological breakthroughs, an inclination towards combined therapies, progressive diagnostic technologies, a transition from oral to injection-based treatments, as well as the utilization of artificial intelligence (AI) in drug development.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20266&type=smp
Who are the Major Competitors in the Skyrizi Market Outlook?
Major companies operating in the skyrizi market are AbbVie Inc.
What Is Fueling Growth in the Skyrizi Market?
Skyrizi Market’s surge is anticipated due to an increasing incidence of psoriasis, a chronic autoimmune disease resulting in an accelerated accumulation of skin cells and consequently, skin surface scaling. The factors contributing to the growth of psoriasis include genetic factors, environmental influences, heightened awareness and diagnosis rates, lifestyle transformations, as well as the increasing impact of stress and immune-associated disorders on overall wellbeing. Skyrizi, a biologic medication targeting interleukin-23 (IL-23), aids in the treatment of psoriasis by specifically inhibiting this particular cytokine, which is vital in the inflammation process. This results in decreased skin inflammation, relief of symptoms such as redness and scaling, and enhanced overall skin clearance in moderate to severe plaque psoriasis patients. For example, in December 2022, the National Psoriasis Foundation (NPF), a U.S.-based nonprofit, estimated that psoriasis affects 8 million Americans and 125 million individuals globally (2-3% of the world’s population). Approximately 30% of individuals with psoriasis also have psoriatic arthritis. Thus, psoriasis’ increasing prevalence propels the expansion of the Skyrizi Market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=20266&type=smp
Which Skyrizi Market Segments Are Growing the Fastest?
The skyrizi market covered in this report is segmented –
1) By Indication: Plaque Psoriasis; Crohn’s Disease; Ulcerative Colitis
2) By Formulation: Pre-Filled Syringes; Vials
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Which Industry Trends Are Shaping the Future of the Skyrizi Market?
One of the key developments in the Skyrizi market revolves around extending the scope of therapeutic indications such as ulcerative colitis in an effort to enhance the effectiveness of treatments for autoimmune diseases. Skyrizi has been sanctioned for the treatment of moderate to severe ulcerative colitis (UC), demonstrating substantial clinical enhancements in patients who have not been receptive to other treatment methods. For instance, in July 2024, the US biopharmaceutical firm, AbbVie Inc., was granted approval by the European Commission for the use of Skyrizi (risankizumab) for the treatment of adult patients suffering from moderately to severely active ulcerative colitis (UC) who have not been responsive to, or can’t tolerate, conventional or biologic therapies. This consent proceeds from affirmative results gathered from the Phase 3 INSPIRE and COMMAND clinical trials, specifically showcasing mucosal healing in patients who have not previously utilized biologic or JAK inhibitor. The administration of Skyrizi involves an initial dose of 1,200 mg, followed by either 180 mg or 360 mg maintenance doses every 8 weeks.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/skyrizi-global-market-report
Which Countries Are Leading the Skyrizi Market?
North America was the largest region in the skyrizi market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the skyrizi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20266
This Report Delivers Insight On:
1. How big is the skyrizi market, and how is it changing globally?
2. Who are the major companies in the skyrizi market, and how are they performing?
3. What are the key opportunities and risks in the skyrizi market right now?
4. Which products or customer segments are growing the most in the skyrizi market?
5. What factors are helping or slowing down the growth of the skyrizi market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model